LMNA-related congenital muscular dystrophy

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC
| LMNA-related congenital muscular dystrophy | |
|---|---|
| Synonyms | L-CMD |
| Pronounce | |
| Specialty | Neurology, Genetics |
| Symptoms | Muscle weakness, Joint contractures, Respiratory difficulties |
| Complications | N/A |
| Onset | Infancy |
| Duration | Chronic |
| Types | N/A |
| Causes | Mutations in the LMNA gene |
| Risks | Family history of the condition |
| Diagnosis | Genetic testing, Muscle biopsy |
| Differential diagnosis | Other forms of muscular dystrophy |
| Prevention | N/A |
| Treatment | Physical therapy, Respiratory support, Orthopedic interventions |
| Medication | N/A |
| Prognosis | Variable, often progressive |
| Frequency | Rare |
| Deaths | N/A |
[edit]
LMNA-related congenital muscular dystrophy is a rare genetic disorder characterized by muscle weakness and wasting (atrophy) that begins at birth or in early infancy. It is caused by mutations in the LMNA gene, which encodes for proteins that are essential components of the nuclear envelope, namely lamin A and lamin C. These proteins play a crucial role in maintaining the structural integrity of the cell nucleus and are involved in various cellular processes.
Clinical Features[edit]
Individuals with LMNA-related congenital muscular dystrophy typically present with muscle weakness that is evident at birth or shortly thereafter. The severity of the condition can vary, but common features include:
- Hypotonia: Decreased muscle tone, often referred to as "floppiness," is a hallmark of the condition.
- Delayed Motor Milestones: Affected infants may experience delays in reaching motor milestones such as sitting, crawling, and walking.
- Joint Contractures: Stiffness and limited range of motion in the joints may develop over time.
- Respiratory Complications: Weakness of the respiratory muscles can lead to breathing difficulties and an increased risk of respiratory infections.
- Cardiac Involvement: Some individuals may develop cardiac problems, including arrhythmias and dilated cardiomyopathy.
Genetic Basis[edit]
The disorder is caused by mutations in the LMNA gene, which is located on chromosome 1q22. The LMNA gene provides instructions for making lamin A and lamin C, which are structural proteins of the nuclear lamina. Mutations in this gene can disrupt the normal function of these proteins, leading to the symptoms observed in LMNA-related congenital muscular dystrophy. The condition is inherited in an autosomal dominant manner, meaning that a single copy of the altered gene in each cell is sufficient to cause the disorder. In some cases, the mutation occurs de novo, meaning it is a new mutation that was not inherited from either parent.
Diagnosis[edit]
Diagnosis of LMNA-related congenital muscular dystrophy is based on clinical evaluation, family history, and genetic testing. Muscle biopsy may show dystrophic changes, but genetic testing is the definitive method for diagnosing the condition. Identifying a mutation in the LMNA gene confirms the diagnosis.
Management[edit]
There is currently no cure for LMNA-related congenital muscular dystrophy, and treatment is primarily supportive. Management strategies may include:
- Physical Therapy: To maintain muscle strength and flexibility and to prevent joint contractures.
- Respiratory Support: Use of ventilatory support devices may be necessary for individuals with significant respiratory muscle weakness.
- Cardiac Monitoring: Regular cardiac evaluations are important to detect and manage any heart-related complications.
- Orthopedic Interventions: Surgery may be required to address severe joint contractures or scoliosis.
Prognosis[edit]
The prognosis for individuals with LMNA-related congenital muscular dystrophy varies depending on the severity of the condition and the presence of complications such as cardiac or respiratory involvement. Early intervention and supportive care can improve quality of life and outcomes for affected individuals.
See also[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian